Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
MoU signed between AIIA and University of Amrita Vishwa Vidhyapeetham for collaboration in the field of Research and Academics in Ayurveda
NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
Getinge has a strong market share in India within several product segments
Digital success is contingent on the way a company organizes itself around technology
Julie is recognized as a highly engaging multi-cultural leader skilled in fluidly partnering with cross-functional teams to deliver results.
Subscribe To Our Newsletter & Stay Updated
